Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis

Abstract

Aim: To assess the efficacy of bexagliflozin in reducing glycated haemoglobin (HbA1c) and the occurrence of side effects in patients with type 2 diabetes (T2DM).Methods: We searched the PubMed, Embase, Cochrane and ClinicalTrials.gov databases for placebo-controlled, randomized clinical trials published up until 15 February 2023. The primary outcome was change in HbA1c. We computed weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs).Results: A total of six studies and 3111 patients were included, of whom 1951 were prescribed bexagliflozin. Compared with placebo, bexagliflozin significantly reduced HbA1c levels (WMD -0.53%; 95% CI -0.75, -0.31), fasting plasma glucose levels (WMD -1.45 mmol/L; 95% CI -2.32, -0.57), systolic blood pressure (WMD -4.66 mmHg; 95% CI -6.41, -2.92), diastolic blood pressure (WMD -2.12 mmHg; 95% CI -3.94, -0.30), body weight overall (WMD -1.61 kg; 95% CI -2.14, -1.07), and body weight in patients with a body mass index >25 kg/m 2 (WMD -2.05 kg; 95% CI -2.78, -1.31). The proportion of patients who achieved HbA1c < 7% was higher in patients who received bexagliflozin as compared with placebo (OR 1.94; 95% CI 1.36-2.78). There were no significant differences between groups regarding side effects such as hypoglycaemia, genital mycotic infection, urinary tract infection, diarrhoea, headache, nausea, polyuria, diabetic ketoacidosis, or all-cause mortality.Conclusions: In this meta-analysis, the use of bexagliflozin was associated with improved clinical and laboratory measures in patients with T2DM compared with placebo, with a similar profile of side effects. These findings support the efficacy of bexagliflozin in the treatment of T2DM.diabetes mellitus, type 2, glycated haemoglobin, sodium-glucose transporter 2 inhibitors | INTRODUCTIONGlycaemic control is a key aspect in the management of patients with type 2 diabetes (T2DM). This effort involves lifestyle changes, blood sugar monitoring, and use of pharmacotherapies. 1 One novel class of drugs for T2DM comprises the sodium-glucose cotransporter-2 (SGLT2) inhibitors, which act directly on the kidneys without requiring insulin secretion. SGLT2 is the primary glucose transporter located in

A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes

“…25 A greater proportion of patients taking bexagliflozin achieved an HbA1c < 7% versus placebo (OR: 1.9, 95% CI: 1.3, 2.7, P < .001; I 2 = 0%). 25…”

“…Evidence from 3 systematic reviews with meta-analysis were identified and are discussed below. 12,24,25…”

“…The efficacy of bexagliflozin in reducing HbA1c was also evaluated in a systematic review and meta-analysis. 25 A total of 6 placebo-controlled studies were included with 3111 patients with T2D, all of which are reviewed herein. 25 Bexagliflozin significantly reduced the primary endpoint, HbA1c as compared with placebo (weighted mean difference: −0.5%, 95% CI: −0.7, −0.3, P < .001, I 2 = 84%).…”

“…25 A total of 6 placebo-controlled studies were included with 3111 patients with T2D, all of which are reviewed herein. 25 Bexagliflozin significantly reduced the primary endpoint, HbA1c as compared with placebo (weighted mean difference: −0.5%, 95% CI: −0.7, −0.3, P < .001, I 2 = 84%). 25 Bexagliflozin also reduced fasting plasma glucose (weighted mean difference: –26.1 mg/dL, 95% CI: –41.8, –10.3, P = .001, I 2 = 89%), systolic blood pressure (weighted mean difference: −4.6 mm Hg, 95% CI: −6.4, −2.9, P < .001, I 2 = 32%), and body weight (weighted mean difference: −1.6 kg, 95% CI: −2.1, −1.0, P < .001, I 2 = 0%).…”

“…25 Bexagliflozin also reduced fasting plasma glucose (weighted mean difference: –26.1 mg/dL, 95% CI: –41.8, –10.3, P = .001, I 2 = 89%), systolic blood pressure (weighted mean difference: −4.6 mm Hg, 95% CI: −6.4, −2.9, P < .001, I 2 = 32%), and body weight (weighted mean difference: −1.6 kg, 95% CI: −2.1, −1.0, P < .001, I 2 = 0%). 25 A greater proportion of patients taking bexagliflozin achieved an HbA1c < 7% versus placebo (OR: 1.9, 95% CI: 1.3, 2.7, P < .001; I 2 = 0%). 25…”